{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:51:05Z","timestamp":1793508665531,"version":"4.5.0"},"reference-count":270,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"vor","delay-in-days":378,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["5P50CA127003"],"award-info":[{"award-number":["5P50CA127003"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["5P50CA236749"],"award-info":[{"award-number":["5P50CA236749"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA101942"],"award-info":[{"award-number":["P50CA101942"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010627","name":"Barr Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010627","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["P01AI56299"],"award-info":[{"award-number":["P01AI56299"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["P01 AI108545"],"award-info":[{"award-number":["P01 AI108545"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunity"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.immuni.2024.01.013","type":"journal-article","created":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T15:33:53Z","timestamp":1707838433000},"page":"223-244","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":145,"title":["The B7:CD28 family and friends: Unraveling coinhibitory interactions"],"prefix":"10.1016","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2187-0147","authenticated-orcid":false,"given":"Kelly P.","family":"Burke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apoorvi","family":"Chaudhri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon J.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlene H.","family":"Sharpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.immuni.2024.01.013_bib1","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1126\/science.169.3950.1042","article-title":"A theory of self-nonself discrimination","volume":"169","author":"Bretscher","year":"1970","journal-title":"Science"},{"key":"10.1016\/j.immuni.2024.01.013_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-3083.1977.tb00317.x","article-title":"A simple conservative explanation of the H-2 restriction of interactions between lymphocytes","volume":"6","author":"Cunningham","year":"1977","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib3","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1182\/blood-2016-04-712612","article-title":"CHAI and LATAIE: new genetic diseases of CTLA-4 checkpoint insufficiency","volume":"128","author":"Lo","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.immuni.2024.01.013_bib4","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1038\/s41591-021-01388-5","article-title":"Inherited PD-1 deficiency underlies tuberculosis and autoimmunity in a child","volume":"27","author":"Ogishi","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.immuni.2024.01.013_bib5","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","article-title":"Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma","volume":"175","author":"Sade-Feldman","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2024.01.013_bib6","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2024.01.013_bib7","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nature05115","article-title":"PD-1 expression on HIV-specific T\u00a0cells is associated with T-cell exhaustion and disease progression","volume":"443","author":"Day","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2024.01.013_bib8","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nature04444","article-title":"Restoring function in exhausted CD8 T\u00a0cells during chronic viral infection","volume":"439","author":"Barber","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2024.01.013_bib9","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.immuni.2016.04.020","article-title":"CD28 Costimulation: From Mechanism to Therapy","volume":"44","author":"Esensten","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2024.01.013_bib10","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.immuni.2016.05.002","article-title":"Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family","volume":"44","author":"Schildberg","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2024.01.013_bib11","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S1074-7613(00)80333-7","article-title":"B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation","volume":"6","author":"Borriello","year":"1997","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2024.01.013_bib12","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/s41573-020-0081-9","article-title":"Targeting co-stimulatory molecules in autoimmune disease","volume":"19","author":"Edner","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.immuni.2024.01.013_bib13","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/imr.12771","article-title":"Inducible T-cell co-stimulator: Signaling mechanisms in T follicular helper cells and beyond","volume":"291","author":"Panneton","year":"2019","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.immuni.2024.01.013_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.938004","article-title":"CD28 and chemokine receptors: Signalling amplifiers at the immunological synapse","volume":"13","author":"Molon","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib15","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.4049\/jimmunol.1502643","article-title":"Genetic and Epigenetic Regulation of PD-1 Expression","volume":"196","author":"Bally","year":"2016","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib16","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41577-023-00867-9","article-title":"Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1","volume":"23","author":"Chamoto","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib17","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nri.2017.108","article-title":"The diverse functions of the PD1 inhibitory pathway","volume":"18","author":"Sharpe","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib18","doi-asserted-by":"crossref","first-page":"4074","DOI":"10.4049\/jimmunol.158.9.4074","article-title":"Synergistic induction of CTLA-4 expression by costimulation with TCR plus CD28 signals mediated by increased transcription and messenger ribonucleic acid stability","volume":"158","author":"Finn","year":"1997","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib19","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.4049\/jimmunol.179.6.3831","article-title":"Induction of the CTLA-4 gene in human lymphocytes is dependent on NFAT binding the proximal promoter","volume":"179","author":"Gibson","year":"2007","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib20","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.bbagrm.2007.10.004","article-title":"The 3' UTR of the human CTLA4 mRNA can regulate mRNA stability and translational efficiency","volume":"1779","author":"Malquori","year":"2008","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.immuni.2024.01.013_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2020.144888","article-title":"Immunomodulatory role for MicroRNAs: Regulation of PD-1\/PD-L1 and CTLA-4 immune checkpoints expression","volume":"754","author":"Skafi","year":"2020","journal-title":"Gene"},{"key":"10.1016\/j.immuni.2024.01.013_bib22","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","article-title":"Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4","volume":"3","author":"Tivol","year":"1995","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2024.01.013_bib23","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1126\/science.270.5238.985","article-title":"Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4","volume":"270","author":"Waterhouse","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.immuni.2024.01.013_bib24","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/nm.3746","article-title":"Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations","volume":"20","author":"Schubert","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.immuni.2024.01.013_bib25","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1126\/science.1255904","article-title":"Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4","volume":"345","author":"Kuehn","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.immuni.2024.01.013_bib26","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1126\/science.aaa1663","article-title":"AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy","volume":"349","author":"Lo","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.immuni.2024.01.013_bib27","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1038\/s41467-019-10812-x","article-title":"Human DEF6 deficiency underlies an immunodeficiency syndrome with systemic autoimmunity and aberrant CTLA-4 homeostasis","volume":"10","author":"Serwas","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.immuni.2024.01.013_bib28","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s12020-016-1096-1","article-title":"CD28\/CTLA-4\/ICOS haplotypes confers susceptibility to Graves' disease and modulates clinical phenotype of disease","volume":"55","author":"Pawlak-Adamska","year":"2017","journal-title":"Endocrine"},{"key":"10.1016\/j.immuni.2024.01.013_bib29","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1084\/jem.189.2.435","article-title":"B7-1 or B7-2 is required to produce the lymphoproliferative phenotype in mice lacking cytotoxic T lymphocyte-associated antigen 4 (CTLA-4)","volume":"189","author":"Mandelbrot","year":"1999","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.immuni.2024.01.013_bib30","doi-asserted-by":"crossref","first-page":"13756","DOI":"10.1073\/pnas.0706509104","article-title":"Induction of autoimmune disease in CTLA-4-\/- mice depends on a specific CD28 motif that is required for in\u00a0vivo costimulation","volume":"104","author":"Tai","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2024.01.013_bib31","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S1074-7613(94)80021-9","article-title":"Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors","volume":"1","author":"Linsley","year":"1994","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2024.01.013_bib32","doi-asserted-by":"crossref","first-page":"26762","DOI":"10.1074\/jbc.271.43.26762","article-title":"Covalent dimerization of CD28\/CTLA-4 and oligomerization of CD80\/CD86 regulate T\u00a0cell costimulatory interactions","volume":"271","author":"Greene","year":"1996","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.immuni.2024.01.013_bib33","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/s41590-022-01289-w","article-title":"Differences in CD80 and CD86 transendocytosis reveal CD86 as a key target for CTLA-4 immune regulation","volume":"23","author":"Kennedy","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib34","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aaw0902","article-title":"CTLA-4-mediated transendocytosis of costimulatory molecules primarily targets migratory dendritic cells","volume":"4","author":"Ovcinnikovs","year":"2019","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib35","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1016\/j.cell.2021.05.027","article-title":"Expansion of tumor-associated Treg cells upon disruption of a CTLA-4-dependent feedback loop","volume":"184","author":"Marangoni","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2024.01.013_bib36","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2023739118","article-title":"Treg-expressed CTLA-4 depletes CD80\/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells","volume":"118","author":"Tekguc","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2024.01.013_bib37","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/ni1003","article-title":"Modulation of tryptophan catabolism by regulatory T\u00a0cells","volume":"4","author":"Fallarino","year":"2003","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib38","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S1074-7613(00)00031-5","article-title":"The CD28 and CTLA-4 receptors associate with the serine\/threonine phosphatase PP2A","volume":"13","author":"Chuang","year":"2000","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2024.01.013_bib39","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.immuni.2004.08.010","article-title":"Role of LAG-3 in regulatory T\u00a0cells","volume":"21","author":"Huang","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2024.01.013_bib40","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.immuni.2014.02.012","article-title":"Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses","volume":"40","author":"Joller","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2024.01.013_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.997376","article-title":"PD-1 and CTLA-4 exert additive control of effector regulatory T\u00a0cells at homeostasis","volume":"14","author":"Pereira","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib42","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aah4569","article-title":"LAG3 limits regulatory T\u00a0cell proliferation and function in autoimmune diabetes","volume":"2","author":"Zhang","year":"2017","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib43","doi-asserted-by":"crossref","first-page":"274","DOI":"10.4049\/jimmunol.182.1.274","article-title":"Ctla-4 controls regulatory T\u00a0cell peripheral homeostasis and is required for suppression of pancreatic islet autoimmunity","volume":"182","author":"Schmidt","year":"2009","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib44","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1126\/science.1160062","article-title":"CTLA-4 control over Foxp3+ regulatory T\u00a0cell function","volume":"322","author":"Wing","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.immuni.2024.01.013_bib45","doi-asserted-by":"crossref","first-page":"E2383","DOI":"10.1073\/pnas.1603892113","article-title":"Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood","volume":"113","author":"Klocke","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2024.01.013_bib46","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1084\/jem.20141030","article-title":"Deletion of CTLA-4 on regulatory T\u00a0cells during adulthood leads to resistance to autoimmunity","volume":"212","author":"Paterson","year":"2015","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.immuni.2024.01.013_bib47","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.immuni.2014.12.006","article-title":"Regulatory T\u00a0cells control antigen-specific expansion of Tfh cell number and humoral immune responses via the coreceptor CTLA-4","volume":"41","author":"Wing","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2024.01.013_bib48","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.immuni.2014.12.005","article-title":"The coinhibitory receptor CTLA-4 controls B cell responses by modulating T follicular helper, T follicular regulatory, and T regulatory cells","volume":"41","author":"Sage","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2024.01.013_bib49","article-title":"T(FH) cells depend on Tcf1-intrinsic HDAC activity to suppress CTLA4 and guard B-cell help function","volume":"118","author":"Li","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2024.01.013_bib50","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1084\/jem.20130579","article-title":"Fc-dependent depletion of tumor-infiltrating regulatory T\u00a0cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma","volume":"210","author":"Simpson","year":"2013","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.immuni.2024.01.013_bib51","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.ccell.2018.02.010","article-title":"Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies","volume":"33","author":"Arce Vargas","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.immuni.2024.01.013_bib52","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1158\/2326-6066.CIR-13-0013","article-title":"Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T\u00a0cells","volume":"1","author":"Selby","year":"2013","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.immuni.2024.01.013_bib53","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1158\/1078-0432.CCR-18-0762","article-title":"Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3(+) Regulatory T Cells (Tregs) in Human Cancers","volume":"25","author":"Sharma","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.immuni.2024.01.013_bib54","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1007\/s00262-022-03170-z","article-title":"Fc-independent functions of anti-CTLA-4 antibodies contribute to anti-tumor efficacy","volume":"71","author":"Sato","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.immuni.2024.01.013_bib55","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2300895120","article-title":"Both intratumoral regulatory T\u00a0cell depletion and CTLA-4 antagonism are required for maximum efficacy of anti-CTLA-4 antibodies","volume":"120","author":"Lax","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2024.01.013_bib56","article-title":"FcyRIIB is a novel immune checkpoint in the tumor microenvironment limiting activity of Treg-targeting antibodies","author":"Knorr","year":"2023","journal-title":"bioRxiv"},{"key":"10.1016\/j.immuni.2024.01.013_bib57","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/s41586-021-03326-4","article-title":"CTLA-4 blockade drives loss of T(reg) stability in glycolysis-low tumours","volume":"591","author":"Zappasodi","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2024.01.013_bib58","doi-asserted-by":"crossref","first-page":"5784","DOI":"10.4049\/jimmunol.162.10.5784","article-title":"Lymphoproliferative disorder in CTLA-4 knockout mice is characterized by CD28-regulated activation of Th2 responses","volume":"162","author":"Khattri","year":"1999","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib59","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41467-020-20874-x","article-title":"CTLA-4 expression by B-1a B cells is essential for immune tolerance","volume":"12","author":"Yang","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.immuni.2024.01.013_bib60","doi-asserted-by":"crossref","first-page":"7316","DOI":"10.4049\/jimmunol.179.11.7316","article-title":"A new role of CTLA-4 on B cells in thymus-dependent immune responses in\u00a0vivo","volume":"179","author":"Quandt","year":"2007","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib61","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.4049\/jimmunol.165.10.5530","article-title":"Inhibition of IgG1 and IgE production by stimulation of the B cell CTLA-4 receptor","volume":"165","author":"Pioli","year":"2000","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib62","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.4049\/jimmunol.2200944","article-title":"Noncanonical B Cells: Characteristics of Uncharacteristic B Cells","volume":"211","author":"Haas","year":"2023","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib63","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.4049\/jimmunol.1801359","article-title":"Leukemic B Cell CTLA-4 Suppresses Costimulation of T Cells","volume":"202","author":"Do","year":"2019","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib64","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.1073\/pnas.1718217115","article-title":"Role of PD-1 during effector CD8 T\u00a0cell differentiation","volume":"115","author":"Ahn","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2024.01.013_bib65","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.immuni.2011.06.015","article-title":"Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T\u00a0cells","volume":"35","author":"Youngblood","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2024.01.013_bib66","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.4049\/jimmunol.181.7.4832","article-title":"NFATc1 regulates PD-1 expression upon T\u00a0cell activation","volume":"181","author":"Oestreich","year":"2008","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib67","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1483302","article-title":"H3K4me3 mediates the NF-kappaB p50 homodimer binding to the pdcd1 promoter to activate PD-1 transcription in T\u00a0cells","volume":"7","author":"Redd","year":"2018","journal-title":"OncoImmunology"},{"key":"10.1016\/j.immuni.2024.01.013_bib68","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.4049\/jimmunol.1003208","article-title":"IFN-alpha directly promotes programmed cell death-1 transcription and limits the duration of T\u00a0cell-mediated immunity","volume":"186","author":"Terawaki","year":"2011","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib69","doi-asserted-by":"crossref","first-page":"872","DOI":"10.4049\/immunohorizons.2100112","article-title":"IL-6\/STAT3 Signaling Axis Enhances and Prolongs Pdcd1 Expression in Murine CD8\u00a0T Cells","volume":"6","author":"Powell","year":"2022","journal-title":"Immunohorizons"},{"key":"10.1016\/j.immuni.2024.01.013_bib70","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/icb.2012.53","article-title":"Notch signaling regulates PD-1 expression during CD8(+) T-cell activation","volume":"91","author":"Mathieu","year":"2013","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.immuni.2024.01.013_bib71","doi-asserted-by":"crossref","first-page":"449","DOI":"10.4049\/jimmunol.1900601","article-title":"PD-1 Expression during Acute Infection Is Repressed through an LSD1-Blimp-1 Axis","volume":"204","author":"Bally","year":"2020","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib72","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1126\/science.aae0491","article-title":"The epigenetic landscape of T\u00a0cell exhaustion","volume":"354","author":"Sen","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.immuni.2024.01.013_bib73","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1126\/science.aaf2807","article-title":"Epigenetic stability of exhausted T\u00a0cells limits durability of reinvigoration by PD-1 blockade","volume":"354","author":"Pauken","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.immuni.2024.01.013_bib74","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1073\/pnas.0610335104","article-title":"Impaired NFAT nuclear translocation results in split exhaustion of virus-specific CD8+ T\u00a0cell functions during chronic viral infection","volume":"104","author":"Agnellini","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2024.01.013_bib75","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.immuni.2014.10.013","article-title":"The transcription factor FoxO1 sustains expression of the inhibitory receptor PD-1 and survival of antiviral CD8(+) T\u00a0cells during chronic infection","volume":"41","author":"Staron","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2024.01.013_bib76","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-019-1324-y","article-title":"TOX is a critical regulator of tumour-specific T\u00a0cell differentiation","volume":"571","author":"Scott","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2024.01.013_bib77","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-019-1326-9","article-title":"TOX reinforces the phenotype and longevity of exhausted T\u00a0cells in chronic viral infection","volume":"571","author":"Alfei","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2024.01.013_bib78","doi-asserted-by":"crossref","first-page":"12410","DOI":"10.1073\/pnas.1905675116","article-title":"TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8(+) T\u00a0cell exhaustion","volume":"116","author":"Seo","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2024.01.013_bib79","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/s41590-021-00979-1","article-title":"Epigenetic scars of CD8(+) T\u00a0cell exhaustion persist after cure of chronic infection in humans","volume":"22","author":"Yates","year":"2021","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib80","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1038\/s41590-021-00975-5","article-title":"Epigenetic scarring of exhausted T\u00a0cells hinders memory differentiation upon eliminating chronic antigenic stimulation","volume":"22","author":"Abdel-Hakeem","year":"2021","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib81","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/s41586-022-05626-9","article-title":"Functional T\u00a0cells are capable of supernumerary cell division and longevity","volume":"614","author":"Soerens","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2024.01.013_bib82","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aba7918","article-title":"TOX is expressed by exhausted and polyfunctional human effector memory CD8(+) T\u00a0cells","volume":"5","author":"Sekine","year":"2020","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib83","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.celrep.2017.07.027","article-title":"Blockage of Core Fucosylation Reduces Cell-Surface Expression of PD-1 and Promotes Anti-tumor Immune Responses of T Cells","volume":"20","author":"Okada","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.immuni.2024.01.013_bib84","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41586-018-0756-0","article-title":"FBXO38 mediates PD-1 ubiquitination and regulates anti-tumour immunity of T\u00a0cells","volume":"564","author":"Meng","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2024.01.013_bib85","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jhep.2019.05.015","article-title":"TOX promotes the exhaustion of antitumor CD8(+) T\u00a0cells by preventing PD1 degradation in hepatocellular carcinoma","volume":"71","author":"Wang","year":"2019","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.immuni.2024.01.013_bib86","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.immuni.2024.01.013_bib87","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/85330","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T\u00a0cell activation","volume":"2","author":"Latchman","year":"2001","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib88","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1126\/science.aaf1292","article-title":"T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition","volume":"355","author":"Hui","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.immuni.2024.01.013_bib89","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20231242","article-title":"TCR ligand potency differentially impacts PD-1 inhibitory effects on diverse signaling pathways","volume":"220","author":"Chan","year":"2023","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.immuni.2024.01.013_bib90","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s42003-020-0845-0","article-title":"Interaction of SHP-2 SH2 domains with PD-1 ITSM induces PD-1 dimerization and SHP-2 activation","volume":"3","author":"Patsoukis","year":"2020","journal-title":"Commun. Biol."},{"key":"10.1016\/j.immuni.2024.01.013_bib91","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.febslet.2004.07.083","article-title":"PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70\/CD3zeta signalosome and downstream signaling to PKCtheta","volume":"574","author":"Sheppard","year":"2004","journal-title":"FEBS Lett."},{"key":"10.1016\/j.immuni.2024.01.013_bib92","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1126\/science.aaf0683","article-title":"Rescue of exhausted CD8 T\u00a0cells by PD-1-targeted therapies is CD28-dependent","volume":"355","author":"Kamphorst","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.immuni.2024.01.013_bib93","doi-asserted-by":"crossref","first-page":"13866","DOI":"10.1073\/pnas.231486598","article-title":"PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine","volume":"98","author":"Okazaki","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2024.01.013_bib94","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.celrep.2018.03.026","article-title":"Shp-2 Is Dispensable for Establishing T Cell Exhaustion and for PD-1 Signaling In\u00a0Vivo","volume":"23","author":"Rota","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.immuni.2024.01.013_bib95","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41590-022-01385-x","article-title":"SHP-2 and PD-1-SHP-2 signaling regulate myeloid cell differentiation and antitumor responses","volume":"24","author":"Christofides","year":"2023","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib96","doi-asserted-by":"crossref","DOI":"10.20900\/immunometab20220007","article-title":"Effects of PD-1 Signaling on Immunometabolic Reprogramming","volume":"4","author":"Boussiotis","year":"2022","journal-title":"Immunometabolism"},{"key":"10.1016\/j.immuni.2024.01.013_bib97","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aay1863","article-title":"Targeted deletion of PD-1 in myeloid cells induces antitumor immunity","volume":"5","author":"Strauss","year":"2020","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib98","doi-asserted-by":"crossref","first-page":"E2480","DOI":"10.1073\/pnas.1305394110","article-title":"Strength of PD-1 signaling differentially affects T-cell effector functions","volume":"110","author":"Wei","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2024.01.013_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107827","article-title":"The PD-1 Pathway Regulates Development and Function of Memory CD8+ T Cells following Respiratory Viral Infection","volume":"31","author":"Pauken","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.immuni.2024.01.013_bib100","doi-asserted-by":"crossref","first-page":"6280","DOI":"10.4049\/jimmunol.1003870","article-title":"Programmed death 1 regulates development of central memory CD8 T\u00a0cells after acute viral infection","volume":"186","author":"Allie","year":"2011","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib101","doi-asserted-by":"crossref","first-page":"11823","DOI":"10.1073\/pnas.0505497102","article-title":"Establishment of NOD-Pdcd1-\/- mice as an efficient animal model of type I diabetes","volume":"102","author":"Wang","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2024.01.013_bib102","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20221920","article-title":"Single-cell profiling reveals unique features of diabetogenic T\u00a0cells in anti-PD-1-induced type 1 diabetes mice","volume":"220","author":"Collier","year":"2023","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.immuni.2024.01.013_bib103","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1084\/jem.20142237","article-title":"Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T\u00a0cells","volume":"212","author":"Odorizzi","year":"2015","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.immuni.2024.01.013_bib104","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1073\/pnas.1917298117","article-title":"PD-1+ stemlike CD8 T\u00a0cells are resident in lymphoid tissues during persistent LCMV infection","volume":"117","author":"Im","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2024.01.013_bib105","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","article-title":"Subsets of exhausted CD8(+) T\u00a0cells differentially mediate tumor control and respond to checkpoint blockade","volume":"20","author":"Miller","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib106","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1038\/nm1482","article-title":"Upregulation of PD-1 expression on HIV-specific CD8+ T\u00a0cells leads to reversible immune dysfunction","volume":"12","author":"Trautmann","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.immuni.2024.01.013_bib107","doi-asserted-by":"crossref","first-page":"e1786","DOI":"10.1002\/onco.13887","article-title":"Systematic Review of PD-1\/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health","volume":"26","author":"Chang","year":"2021","journal-title":"Oncol."},{"key":"10.1016\/j.immuni.2024.01.013_bib108","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nature19330","article-title":"Defining CD8+ T\u00a0cells that provide the proliferative burst after PD-1 therapy","volume":"537","author":"Im","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2024.01.013_bib109","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.immuni.2020.04.014","article-title":"Developmental Relationships of Four Exhausted CD8(+) T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms","volume":"52","author":"Beltra","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2024.01.013_bib110","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","article-title":"Intratumoral Tcf1(+)PD-1(+)CD8(+) T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy","volume":"50","author":"Siddiqui","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2024.01.013_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113155","article-title":"Reciprocal transmission of activating and inhibitory signals and cell fate in regenerating T\u00a0cells","volume":"42","author":"Wang","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.immuni.2024.01.013_bib112","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adg0539","article-title":"PD-1 blockade increases the self-renewal of stem-like CD8 T\u00a0cells to compensate for their accelerated differentiation into effectors","volume":"8","author":"Gill","year":"2023","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib113","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adg0878","article-title":"Sustained CD28 costimulation is required for self-renewal and differentiation of TCF-1(+) PD-1(+) CD8 T\u00a0cells","volume":"8","author":"Humblin","year":"2023","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib114","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.immuni.2022.12.002","article-title":"CD8(+) T\u00a0cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor","volume":"56","author":"Prokhnevska","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2024.01.013_bib115","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aaw1217","article-title":"PD-1(hi) CD8(+) resident memory T\u00a0cells balance immunity and fibrotic sequelae","volume":"4","author":"Wang","year":"2019","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib116","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.ccell.2023.01.004","article-title":"Intratumoral CD8(+) T\u00a0cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer","volume":"41","author":"Virassamy","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.immuni.2024.01.013_bib117","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1038\/icb.2017.62","article-title":"Maintenance of PD-1 on brain-resident memory CD8 T\u00a0cells is antigen independent","volume":"95","author":"Shwetank","year":"2017","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.immuni.2024.01.013_bib118","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1016\/j.cell.2022.06.018","article-title":"Tissue-resident memory and circulating T\u00a0cells are early responders to pre-surgical cancer immunotherapy","volume":"185","author":"Luoma","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2024.01.013_bib119","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41586-021-03752-4","article-title":"Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers","volume":"596","author":"Caushi","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2024.01.013_bib120","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.cell.2020.06.001","article-title":"Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy","volume":"182","author":"Luoma","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2024.01.013_bib121","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1016\/j.celrep.2019.11.056","article-title":"Tissue-Resident Memory T Cells Mediate Immune Homeostasis in the Human Pancreas through the PD-1\/PD-L1 Pathway","volume":"29","author":"Weisberg","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.immuni.2024.01.013_bib122","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20182232","article-title":"PD-1 restraint of regulatory T\u00a0cell suppressive activity is critical for immune tolerance","volume":"218","author":"Tan","year":"2021","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.immuni.2024.01.013_bib123","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/s41590-022-01170-w","article-title":"PD-L1-PD-1 interactions limit effector regulatory T\u00a0cell populations at homeostasis and during infection","volume":"23","author":"Perry","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib124","doi-asserted-by":"crossref","first-page":"9999","DOI":"10.1073\/pnas.1822001116","article-title":"PD-1(+) regulatory T\u00a0cells amplified by PD-1 blockade promote hyperprogression of cancer","volume":"116","author":"Kamada","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2024.01.013_bib125","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/s41590-020-0769-3","article-title":"The PD-1 expression balance between effector and regulatory T\u00a0cells predicts the clinical efficacy of PD-1 blockade therapies","volume":"21","author":"Kumagai","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib126","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/ni.3577","article-title":"Foxp3 and Toll-like receptor signaling balance T(reg) cell anabolic metabolism for suppression","volume":"17","author":"Gerriets","year":"2016","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib127","first-page":"OF1","article-title":"PD-1 Expression on Intratumoral Regulatory T Cells is Associated with Lack of Benefit from Anti-PD-1 Therapy in Metastatic Clear Cell Renal Cell Carcinoma Patients","author":"Denize","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.immuni.2024.01.013_bib128","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/ni.2496","article-title":"The receptor PD-1 controls follicular regulatory T\u00a0cells in the lymph nodes and blood","volume":"14","author":"Sage","year":"2013","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib129","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.4049\/jimmunol.1701231","article-title":"Dendritic Cell PD-L1 Limits Autoimmunity and Follicular T Cell Differentiation and Function","volume":"200","author":"Sage","year":"2018","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib130","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/ni.1877","article-title":"PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells","volume":"11","author":"Good-Jacobson","year":"2010","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib131","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1158\/2159-8290.CD-15-1408","article-title":"PD-1hi Identifies a Novel Regulatory B-cell Population in Human Hepatoma That Promotes Disease Progression","volume":"6","author":"Xiao","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.immuni.2024.01.013_bib132","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature20810","article-title":"Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis","volume":"542","author":"Rao","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2024.01.013_bib133","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.add4947","article-title":"Anti-PD-1 antibodies recognizing the membrane-proximal region are PD-1 agonists that can down-regulate inflammatory diseases","volume":"8","author":"Suzuki","year":"2023","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib134","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1056\/NEJMoa2209856","article-title":"A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis","volume":"388","author":"Tuttle","year":"2023","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2024.01.013_bib135","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1093\/intimm\/10.10.1563","article-title":"Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses","volume":"10","author":"Nishimura","year":"1998","journal-title":"Int. Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib136","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.4049\/jimmunol.2100336","article-title":"The PD-1 Regulatory Axis Inhibits T Cell-Independent B Cell Memory Generation and Reactivation","volume":"207","author":"Spurrier","year":"2021","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib137","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.4049\/jimmunol.1401673","article-title":"PD-1 suppresses protective immunity to Streptococcus pneumoniae through a B cell-intrinsic mechanism","volume":"194","author":"McKay","year":"2015","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib138","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.4049\/jimmunol.1302091","article-title":"CTLA-4 is expressed by activated mouse NK cells and inhibits NK Cell IFN-gamma production in response to mature dendritic cells","volume":"192","author":"Stojanovic","year":"2014","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib139","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1172\/JCI99317","article-title":"Contribution of NK cells to immunotherapy mediated by PD-1\/PD-L1 blockade","volume":"128","author":"Hsu","year":"2018","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.immuni.2024.01.013_bib140","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abj3286","article-title":"When killers become thieves: Trogocytosed PD-1 inhibits NK cells in cancer","volume":"8","author":"Hasim","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.immuni.2024.01.013_bib141","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1038\/s41467-020-17813-1","article-title":"PD-1 pathway regulates ILC2 metabolism and PD-1 agonist treatment ameliorates airway hyperreactivity","volume":"11","author":"Helou","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.immuni.2024.01.013_bib142","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/s41590-021-00943-z","article-title":"Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma","volume":"22","author":"Jacquelot","year":"2021","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib143","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/j.celrep.2018.10.091","article-title":"PD-1 Is Involved in the Dysregulation of Type 2 Innate Lymphoid Cells in a Murine Model of Obesity","volume":"25","author":"Oldenhove","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.immuni.2024.01.013_bib144","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature22396","article-title":"PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity","volume":"545","author":"Gordon","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2024.01.013_bib145","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.ccell.2023.02.005","article-title":"Tumor PD-L1 engages myeloid PD-1 to suppress type I interferon to impair cytotoxic T lymphocyte recruitment","volume":"41","author":"Klement","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.immuni.2024.01.013_bib146","doi-asserted-by":"crossref","first-page":"5811","DOI":"10.1182\/blood-2009-02-203141","article-title":"PD-1 on dendritic cells impedes innate immunity against bacterial infection","volume":"113","author":"Yao","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.immuni.2024.01.013_bib147","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1016\/j.neuron.2023.05.022","article-title":"PD-L1\/PD-1 checkpoint pathway regulates hippocampal neuronal excitability and learning and memory behavior","volume":"111","author":"Zhao","year":"2023","journal-title":"Neuron"},{"key":"10.1016\/j.immuni.2024.01.013_bib148","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.immuni.2019.03.004","article-title":"Negative Co-stimulation Constrains T Cell Differentiation by Imposing Boundaries on Possible Cell States","volume":"50","author":"Wei","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2024.01.013_bib149","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2024.01.013_bib150","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.immuni.2024.01.013_bib151","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1158\/2159-8290.CD-20-0856","article-title":"A genetic mouse model recapitulates immune checkpoint inhibitor-associated myocarditis and supports a mechanism-based therapeutic intervention","volume":"11","author":"Wei","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.immuni.2024.01.013_bib152","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41586-022-05432-3","article-title":"T cells specific for alpha-myosin drive immunotherapy-related myocarditis","volume":"611","author":"Axelrod","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2024.01.013_bib153","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.immuni.2007.05.016","article-title":"Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T\u00a0cell responses","volume":"27","author":"Butte","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2024.01.013_bib154","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1084\/jem.20130790","article-title":"RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance","volume":"211","author":"Xiao","year":"2014","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.immuni.2024.01.013_bib155","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1158\/2326-6066.CIR-17-0316","article-title":"PD-L1 Binds to B7-1 Only In Cis on the Same Cell Surface","volume":"6","author":"Chaudhri","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.immuni.2024.01.013_bib156","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1126\/science.aav7062","article-title":"Restriction of PD-1 function by cis-PD-L1\/CD80 interactions is required for optimal T\u00a0cell responses","volume":"364","author":"Sugiura","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.immuni.2024.01.013_bib157","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.immuni.2019.11.003","article-title":"PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways","volume":"51","author":"Zhao","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2024.01.013_bib158","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0233578","article-title":"Mechanistic dissection of the PD-L1:B7-1 co-inhibitory immune complex","volume":"15","author":"Garrett-Thomson","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.immuni.2024.01.013_bib159","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.immuni.2023.04.005","article-title":"cis-B7:CD28 interactions at invaginated synaptic membranes provide CD28 co-stimulation and promote CD8(+) T\u00a0cell function and anti-tumor immunity","volume":"56","author":"Zhao","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2024.01.013_bib160","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41590-021-01125-7","article-title":"PD-1 agonism by anti-CD80 inhibits T\u00a0cell activation and alleviates autoimmunity","volume":"23","author":"Sugiura","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib161","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.4049\/jimmunol.1003496","article-title":"The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T\u00a0cells in\u00a0vivo","volume":"187","author":"Paterson","year":"2011","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib162","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.4049\/jimmunol.1100056","article-title":"The novel costimulatory programmed death ligand 1\/B7.1 pathway is functional in inhibiting alloimmune responses in\u00a0vivo","volume":"187","author":"Yang","year":"2011","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib163","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1182\/blood-2010-01-265975","article-title":"B7-H1\/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance","volume":"116","author":"Park","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.immuni.2024.01.013_bib164","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41577-019-0264-y","article-title":"The importance of exosomal PDL1 in tumour immune evasion","volume":"20","author":"Daassi","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib165","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00262-018-2282-1","article-title":"A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression","volume":"68","author":"Mahoney","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.immuni.2024.01.013_bib166","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1158\/2326-6066.CIR-16-0329","article-title":"Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade","volume":"5","author":"Zhou","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.immuni.2024.01.013_bib167","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1158\/1078-0432.CCR-10-0250","article-title":"Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma","volume":"17","author":"Frigola","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.immuni.2024.01.013_bib168","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00262-019-02437-2","article-title":"Proteolytic processing of PD-L1 by ADAM proteases in breast cancer cells","volume":"69","author":"Romero","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.immuni.2024.01.013_bib169","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.cell.2019.02.016","article-title":"Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory","volume":"177","author":"Poggio","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2024.01.013_bib170","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41586-018-0392-8","article-title":"Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response","volume":"560","author":"Chen","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2024.01.013_bib171","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.trecan.2020.03.002","article-title":"Exosomal PD-L1: Roles in Tumor Progression and Immunotherapy","volume":"6","author":"Morrissey","year":"2020","journal-title":"Trends Cancer"},{"key":"10.1016\/j.immuni.2024.01.013_bib172","doi-asserted-by":"crossref","first-page":"eaar2766","DOI":"10.1126\/sciadv.aar2766","article-title":"Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles","volume":"4","author":"Ricklefs","year":"2018","journal-title":"Sci. Adv."},{"key":"10.1016\/j.immuni.2024.01.013_bib173","article-title":"Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab","volume":"7","author":"Costantini","year":"2018","journal-title":"OncoImmunology"},{"key":"10.1016\/j.immuni.2024.01.013_bib174","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1084\/jem.20180870","article-title":"Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer","volume":"216","author":"Gong","year":"2019","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.immuni.2024.01.013_bib175","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.153323","article-title":"Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylation","volume":"7","author":"Sagawa","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.immuni.2024.01.013_bib176","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1158\/1078-0432.CCR-17-2664","article-title":"Clinical Significance of PD-L1(+) Exosomes in Plasma of Head and Neck Cancer Patients","volume":"24","author":"Theodoraki","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.immuni.2024.01.013_bib177","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1245\/s10434-019-07431-7","article-title":"Exosomal PD-L1 Retains Immunosuppressive Activity and is Associated with Gastric Cancer Prognosis","volume":"26","author":"Fan","year":"2019","journal-title":"Ann. Surg Oncol."},{"key":"10.1016\/j.immuni.2024.01.013_bib178","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1038\/leu.2014.137","article-title":"High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial","volume":"28","author":"Rossille","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.immuni.2024.01.013_bib179","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1007\/s00262-023-03552-x","article-title":"The influence of plasma sPD-L1 concentration on the effectiveness of immunotherapy in advanced NSCLC patients","volume":"72","author":"Chmielewska","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.immuni.2024.01.013_bib180","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.774131","article-title":"Prognostic Role of Soluble Programmed Death Ligand 1 in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis","volume":"11","author":"Liao","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.immuni.2024.01.013_bib181","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/PAI.0000000000000602","article-title":"The Multiple Faces of Programmed Cell Death Ligand 1 Expression in Malignant and Nonmalignant Cells","volume":"27","author":"Parra","year":"2019","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"10.1016\/j.immuni.2024.01.013_bib182","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.trecan.2021.03.003","article-title":"Extracellular and nuclear PD-L1 in modulating cancer immunotherapy","volume":"7","author":"Xiong","year":"2021","journal-title":"Trends Cancer"},{"key":"10.1016\/j.immuni.2024.01.013_bib183","doi-asserted-by":"crossref","first-page":"R48","DOI":"10.1186\/bcr2605","article-title":"Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic molecule","volume":"12","author":"Ghebeh","year":"2010","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.immuni.2024.01.013_bib184","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/s41422-020-0315-8","article-title":"Regulation of sister chromatid cohesion by nuclear PD-L1","volume":"30","author":"Yu","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.immuni.2024.01.013_bib185","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1038\/s41418-020-00651-5","article-title":"KPNB1-mediated nuclear translocation of PD-L1 promotes non-small cell lung cancer cell proliferation via the Gas6\/MerTK signaling pathway","volume":"28","author":"Du","year":"2021","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.immuni.2024.01.013_bib186","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/s41556-020-0562-4","article-title":"Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy","volume":"22","author":"Gao","year":"2020","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.immuni.2024.01.013_bib187","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/s41556-020-0575-z","article-title":"PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis","volume":"22","author":"Hou","year":"2020","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.immuni.2024.01.013_bib188","doi-asserted-by":"crossref","first-page":"14122","DOI":"10.1074\/jbc.M410034200","article-title":"DRAGON, a bone morphogenetic protein co-receptor","volume":"280","author":"Samad","year":"2005","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.immuni.2024.01.013_bib189","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.mcn.2009.11.003","article-title":"RGMb controls aggregation and migration of Neogenin-positive cells in\u00a0vitro and in\u00a0vivo","volume":"43","author":"Conrad","year":"2010","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.immuni.2024.01.013_bib190","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jaci.2018.12.1022","article-title":"Blockade of RGMb inhibits allergen-induced airways disease","volume":"144","author":"Yu","year":"2019","journal-title":"J.\u00a0Allergy Clin. Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib191","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.tcb.2016.11.009","article-title":"RGMs: Structural Insights, Molecular Regulation, and Downstream Signaling","volume":"27","author":"Siebold","year":"2017","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.immuni.2024.01.013_bib192","doi-asserted-by":"crossref","first-page":"6984","DOI":"10.1038\/s41598-019-43068-y","article-title":"RGMB enhances the suppressive activity of the monomeric secreted form of CTLA-4","volume":"9","author":"Sekiya","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.immuni.2024.01.013_bib193","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.4049\/jimmunol.1002047","article-title":"Dragon (repulsive guidance molecule b) inhibits IL-6 expression in macrophages","volume":"186","author":"Xia","year":"2011","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib194","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1038\/cmi.2017.17","article-title":"B7-DC (PD-L2) costimulation of CD4(+) T-helper 1 response via RGMb","volume":"15","author":"Nie","year":"2018","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib195","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.960329","article-title":"Immunoregulatory effects of RGMb in gut inflammation","volume":"13","author":"P\u00e9rez-Cruz","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib196","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.648915","article-title":"Repulsive Guidance Molecule b Deficiency Induces Gut Microbiota Dysbiosis and Increases the Susceptibility to Intestinal Inflammation in Mice","volume":"12","author":"Shi","year":"2021","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.immuni.2024.01.013_bib197","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41586-023-06026-3","article-title":"Targeting PD-L2-RGMb overcomes microbiome-related immunotherapy resistance","volume":"617","author":"Park","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2024.01.013_bib198","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/14712598.2020.1693540","article-title":"Role of Inducible Co-Stimulator (ICOS) in cancer immunotherapy","volume":"20","author":"Amatore","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.immuni.2024.01.013_bib199","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12943-023-01751-9","article-title":"New frontiers in immune checkpoint B7-H3 (CD276) research and drug development","volume":"22","author":"Getu","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.immuni.2024.01.013_bib200","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2019.104008","article-title":"B7-H4, a promising target for immunotherapy","volume":"347","author":"Wang","year":"2020","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib201","doi-asserted-by":"crossref","first-page":"9879","DOI":"10.1073\/pnas.1303524110","article-title":"HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function","volume":"110","author":"Zhao","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2024.01.013_bib202","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1038\/ncomms3043","article-title":"B7-H5 costimulates human T\u00a0cells via CD28H","volume":"4","author":"Zhu","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.immuni.2024.01.013_bib203","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1158\/1078-0432.CCR-14-1495","article-title":"Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein","volume":"21","author":"Janakiram","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.immuni.2024.01.013_bib204","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1006\/geno.1999.5877","article-title":"Endogenous retroviruses provide the primary polyadenylation signal for two new human genes (HHLA2 and HHLA3)","volume":"59","author":"Mager","year":"1999","journal-title":"Genomics"},{"key":"10.1016\/j.immuni.2024.01.013_bib205","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1186\/s12885-023-11496-9","article-title":"Regulation of HHLA2 expression in kidney cancer and myeloid cells","volume":"23","author":"Shigemura","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.immuni.2024.01.013_bib206","article-title":"HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma","volume":"8","author":"Zhou","year":"2020","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.immuni.2024.01.013_bib207","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s40425-019-0554-8","article-title":"HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1","volume":"7","author":"Jing","year":"2019","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.immuni.2024.01.013_bib208","article-title":"B7 score and T\u00a0cell infiltration stratify immune status in prostate cancer","volume":"9","author":"Zhou","year":"2021","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.immuni.2024.01.013_bib209","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1158\/2326-6066.CIR-20-0315","article-title":"KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1","volume":"9","author":"Bhatt","year":"2021","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.immuni.2024.01.013_bib210","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1158\/1078-0432.CCR-17-2924","article-title":"Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1-Negative Human Lung Cancers","volume":"24","author":"Cheng","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.immuni.2024.01.013_bib211","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1002\/cam4.4081","article-title":"HHLA2 deficiency inhibits non-small cell lung cancer progression and THP-1 macrophage M2 polarization","volume":"10","author":"Sun","year":"2021","journal-title":"Cancer Med."},{"key":"10.1016\/j.immuni.2024.01.013_bib212","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1007\/s10753-022-01644-x","article-title":"HHLA2 Activates the JAK\/STAT Signaling Pathway by Binding to TMIGD2 in Hepatocellular Carcinoma Cells","volume":"45","author":"Guo","year":"2022","journal-title":"Inflammation"},{"key":"10.1016\/j.immuni.2024.01.013_bib213","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.831101","article-title":"Comprehensive Analysis of HHLA2 as a Prognostic Biomarker and Its Association With Immune Infiltrates in Hepatocellular Carcinoma","volume":"13","author":"Ding","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib214","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1093\/ajcp\/aqab221","article-title":"HHLA2 Immune Checkpoint Is a Novel Prognostic Predictor in Hepatocellular Carcinoma","volume":"158","author":"Liao","year":"2022","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.immuni.2024.01.013_bib215","article-title":"HHLA2\u00a0Used as a Potential Prognostic and Immunological Biomarker and Correlated with Tumor Microenvironment in Pan-Cancer","volume":"2022","author":"Yang","year":"2022","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.immuni.2024.01.013_bib216","first-page":"2309","article-title":"HHLA2 is a novel prognostic predictor and potential therapeutic target in malignant glioma","volume":"42","author":"Qi","year":"2019","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.immuni.2024.01.013_bib217","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1038\/s41423-020-0361-7","article-title":"B7-H7 (HHLA2) inhibits T-cell activation and proliferation in the presence of TCR and CD28 signaling","volume":"18","author":"Rieder","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib218","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abf9792","article-title":"KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target","volume":"6","author":"Wei","year":"2021","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib219","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1158\/2326-6066.CIR-18-0733","article-title":"CD28 Homolog Is a Strong Activator of Natural Killer Cells for Lysis of B7H7(+) Tumor Cells","volume":"7","author":"Zhuang","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.immuni.2024.01.013_bib220","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1016\/j.celrep.2019.07.073","article-title":"Structure and Functional Binding Epitope of V-domain Ig Suppressor of T Cell Activation","volume":"28","author":"Mehta","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.immuni.2024.01.013_bib221","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.it.2020.12.008","article-title":"VISTA: A Mediator of Quiescence and a Promising Target in Cancer Immunotherapy","volume":"42","author":"Yuan","year":"2021","journal-title":"Trends Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib222","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.4049\/jimmunol.1100660","article-title":"Cutting edge: A monoclonal antibody specific for the programmed death-1 homolog prevents graft-versus-host disease in mouse models","volume":"187","author":"Flies","year":"2011","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib223","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/imm.13001","article-title":"VSIG-3 as a ligand of VISTA inhibits human T-cell function","volume":"156","author":"Wang","year":"2019","journal-title":"Immunology"},{"key":"10.1016\/j.immuni.2024.01.013_bib224","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41586-019-1674-5","article-title":"VISTA is an acidic pH-selective ligand for PSGL-1","volume":"574","author":"Johnston","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2024.01.013_bib225","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1007\/s10637-022-01244-4","article-title":"A small molecule inhibitor of VSIG-8 prevents its binding to VISTA","volume":"40","author":"Chen","year":"2022","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.immuni.2024.01.013_bib226","doi-asserted-by":"crossref","DOI":"10.3390\/antib12030055","article-title":"Conditionally Active, pH-Sensitive Immunoregulatory Antibodies Targeting VISTA and CTLA-4 Lead an Emerging Class of Cancer Therapeutics","volume":"12","author":"Smith","year":"2023","journal-title":"Antibodies"},{"key":"10.1016\/j.immuni.2024.01.013_bib227","first-page":"2023","article-title":"SNS-101, a clinical-stage pH-dependent and TME-selective anti-VISTA antibody with favorable pharmacokinetic and safety characteristics, promotes anti tumoral M1 macrophage polarization in PD-1 refractory settings","volume":"20","author":"Smith","year":"2023","journal-title":"held in Milan, Italy, September"},{"key":"10.1016\/j.immuni.2024.01.013_bib228","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1182\/blood.V88.8.3010.bloodjournal8883010","article-title":"P-selectin glycoprotein ligand-1 is broadly expressed in cells of myeloid, lymphoid, and dendritic lineage and in some nonhematopoietic cells","volume":"88","author":"Laszik","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.immuni.2024.01.013_bib229","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.immuni.2016.04.015","article-title":"PSGL-1 Is an Immune Checkpoint Regulator that Promotes T Cell Exhaustion","volume":"44","author":"Tinoco","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2024.01.013_bib230","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2019.101308","article-title":"VISTA: a novel immunotherapy target for normalizing innate and adaptive immunity","volume":"42","author":"ElTanbouly","year":"2019","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib231","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1084\/jem.20100619","article-title":"VISTA, a novel mouse Ig superfamily ligand that negatively regulates T\u00a0cell responses","volume":"208","author":"Wang","year":"2011","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.immuni.2024.01.013_bib232","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nm.4308","article-title":"VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer","volume":"23","author":"Gao","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.immuni.2024.01.013_bib233","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1007\/s13238-019-0642-z","article-title":"Analysis of VISTA expression and function in renal cell carcinoma highlights VISTA as a potential target for immunotherapy","volume":"10","author":"Hong","year":"2019","journal-title":"Protein Cell"},{"key":"10.1016\/j.immuni.2024.01.013_bib234","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.cell.2020.09.064","article-title":"CNS-Native Myeloid Cells Drive Immune Suppression in the Brain Metastatic Niche through Cxcl10","volume":"183","author":"Guldner","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2024.01.013_bib235","doi-asserted-by":"crossref","first-page":"6682","DOI":"10.1073\/pnas.1420370112","article-title":"Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses","volume":"112","author":"Liu","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2024.01.013_bib236","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1158\/0008-5472.CAN-13-1506","article-title":"VISTA Regulates the Development of Protective Antitumor Immunity","volume":"74","author":"Le Mercier","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.immuni.2024.01.013_bib237","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1158\/2326-6066.CIR-22-0759","article-title":"VISTA Expression on Cancer-Associated Endothelium Selectively Prevents T-cell Extravasation","volume":"11","author":"Luk","year":"2023","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.immuni.2024.01.013_bib238","doi-asserted-by":"crossref","DOI":"10.1126\/science.aay0524","article-title":"VISTA is a checkpoint regulator for naive T\u00a0cell quiescence and peripheral tolerance","volume":"367","author":"ElTanbouly","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.immuni.2024.01.013_bib239","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax1159","article-title":"PD-1H (VISTA)-mediated suppression of autoimmunity in systemic and cutaneous lupus erythematosus","volume":"11","author":"Han","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.immuni.2024.01.013_bib240","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1158\/2326-6066.CIR-14-0072","article-title":"VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy","volume":"2","author":"Lines","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.immuni.2024.01.013_bib241","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1158\/2326-6066.CIR-18-0489","article-title":"Immune-Checkpoint Protein VISTA Regulates Antitumor Immunity by Controlling Myeloid Cell-Mediated Inflammation and Immunosuppression","volume":"7","author":"Xu","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.immuni.2024.01.013_bib242","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1038\/s41598-017-01411-1","article-title":"Immune-checkpoint protein VISTA critically regulates the IL-23\/IL-17 inflammatory axis","volume":"7","author":"Li","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.immuni.2024.01.013_bib243","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/cmi.2017.16","article-title":"A crucial role of the PD-1H coinhibitory receptor in suppressing experimental asthma","volume":"15","author":"Liu","year":"2018","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib244","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/art.40020","article-title":"VISTA Deficiency Accelerates the Development of Fatal Murine Lupus Nephritis","volume":"69","author":"Ceeraz","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.immuni.2024.01.013_bib245","series-title":"SNS-101, a Monoclonal Antibody that Is Highly Selective for VISTA in the Tumor Microenvironment, Demonstrates Favorable Pharmacokinetic and Cytokine Release Characteristics and Potentiates Anti-PD-1 Responsiveness","author":"Thisted","year":"2022"},{"key":"10.1016\/j.immuni.2024.01.013_bib246","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1002\/eji.200425227","article-title":"Frontline: Characterization of BT3 molecules belonging to the B7 family expressed on immune cells","volume":"34","author":"Compte","year":"2004","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib247","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1126\/science.aay2767","article-title":"BTN3A1 governs antitumor responses by coordinating alphabeta and gammadelta T\u00a0cells","volume":"369","author":"Payne","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.immuni.2024.01.013_bib248","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1182\/blood-2012-05-430470","article-title":"Key implication of CD277\/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human gammadelta T-cell subset","volume":"120","author":"Harly","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.immuni.2024.01.013_bib249","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1146\/annurev-immunol-032713-120216","article-title":"gammadelta T\u00a0cells: first line of defense and beyond","volume":"32","author":"Chien","year":"2014","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib250","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.semcdb.2018.02.007","article-title":"Butyrophilin3A proteins and Vgamma9Vdelta2 T\u00a0cell activation","volume":"84","author":"Gu","year":"2018","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.immuni.2024.01.013_bib251","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.immuni.2014.03.003","article-title":"The intracellular B30.2 domain of butyrophilin 3A1 binds phosphoantigens to mediate activation of human Vgamma9Vdelta2 T\u00a0cells","volume":"40","author":"Sandstrom","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2024.01.013_bib252","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.chembiol.2014.06.006","article-title":"Synthesis of a phosphoantigen prodrug that potently activates Vgamma9Vdelta2 T-lymphocytes","volume":"21","author":"Hsiao","year":"2014","journal-title":"Chem. Biol."},{"key":"10.1016\/j.immuni.2024.01.013_bib253","doi-asserted-by":"crossref","first-page":"E7311","DOI":"10.1073\/pnas.1707547114","article-title":"Phosphoantigen-induced conformational change of butyrophilin 3A1 (BTN3A1) and its implication on Vgamma9Vdelta2 T\u00a0cell activation","volume":"114","author":"Gu","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2024.01.013_bib254","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/s41586-023-06525-3","article-title":"Phosphoantigens glue butyrophilin 3A1 and 2A1 to activate Vgamma9Vdelta2 T\u00a0cells","volume":"621","author":"Yuan","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2024.01.013_bib255","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109359","article-title":"BTN2A1, an immune checkpoint targeting Vgamma9Vdelta2 T\u00a0cell cytotoxicity against malignant cells","volume":"36","author":"Cano","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.immuni.2024.01.013_bib256","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/s41586-023-06482-x","article-title":"CRISPR screens decode cancer cell pathways that trigger gammadelta T\u00a0cell detection","volume":"621","author":"Mamedov","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2024.01.013_bib257","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abj0835","article-title":"Development of ICT01, a first-in-class, anti-BTN3A antibody for activating Vgamma9Vdelta2 T\u00a0cell-mediated antitumor immune response","volume":"13","author":"De Gassart","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.immuni.2024.01.013_bib258","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.4049\/jimmunol.178.3.1523","article-title":"BTNL2, a butyrophilin\/B7-like molecule, is a negative costimulatory molecule modulated in intestinal inflammation","volume":"178","author":"Arnett","year":"2007","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib259","doi-asserted-by":"crossref","first-page":"7354","DOI":"10.4049\/jimmunol.176.12.7354","article-title":"BTNL2, a butyrophilin-like molecule that functions to inhibit T\u00a0cell activation","volume":"176","author":"Nguyen","year":"2006","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib260","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1146\/annurev-immunol-041015-055435","article-title":"Regulation of Immunity by Butyrophilins","volume":"34","author":"Rhodes","year":"2016","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib261","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/s41467-021-27936-8","article-title":"Cancer cell-expressed BTNL2 facilitates tumour immune escape via engagement with IL-17A-producing gammadelta T\u00a0cells","volume":"13","author":"Du","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.immuni.2024.01.013_bib262","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.4049\/jimmunol.1201760","article-title":"Butyrophilin-like 2 modulates B7 costimulation to induce Foxp3 expression and regulatory T\u00a0cell development in mature T\u00a0cells","volume":"190","author":"Swanson","year":"2013","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2024.01.013_bib263","article-title":"The BTNL2 G16071A gene polymorphism increases granulomatous disease susceptibility: A meta-analysis including FPRP test of 8710 participants","volume":"95","author":"Tong","year":"2016","journal-title":"Medicine (Baltim.)"},{"key":"10.1016\/j.immuni.2024.01.013_bib264","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/ng1519","article-title":"Sarcoidosis is associated with a truncating splice site mutation in BTNL2","volume":"37","author":"Valentonyte","year":"2005","journal-title":"Nat. Genet."},{"key":"10.1016\/j.immuni.2024.01.013_bib265","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/jhg.2013.2","article-title":"Exome sequencing identifies novel rheumatoid arthritis-susceptible variants in the BTNL2","volume":"58","author":"Mitsunaga","year":"2013","journal-title":"J.\u00a0Hum. Genet."},{"key":"10.1016\/j.immuni.2024.01.013_bib266","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/iid3.105","article-title":"Altered expression of Butyrophilin (BTN) and BTN-like (BTNL) genes in intestinal inflammation and colon cancer","volume":"4","author":"Lebrero-Fern\u00e1ndez","year":"2016","journal-title":"Immun. Inflamm. Dis."},{"key":"10.1016\/j.immuni.2024.01.013_bib267","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1158\/1055-9965.EPI-13-0345","article-title":"Germline missense variants in the BTNL2 gene are associated with prostate cancer susceptibility","volume":"22","author":"Fitzgerald","year":"2013","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.immuni.2024.01.013_bib268","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1093\/infdis\/jiv217","article-title":"The T-Cell Inhibitory Molecule Butyrophilin-Like 2 Is Up-regulated in Mild Plasmodium falciparum Infection and Is Protective During Experimental Cerebral Malaria","volume":"212","author":"Subramaniam","year":"2015","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.immuni.2024.01.013_bib269","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/s42003-021-02438-x","article-title":"Butyrophilin-like 2 regulates site-specific adaptations of intestinal gammadelta intraepithelial lymphocytes","volume":"4","author":"Panea","year":"2021","journal-title":"Commun. Biol."},{"key":"10.1016\/j.immuni.2024.01.013_bib270","doi-asserted-by":"crossref","DOI":"10.15252\/embr.202256034","article-title":"BTNL2 promotes colitis-associated tumorigenesis in mice by regulating IL-22 production","volume":"24","author":"Peng","year":"2023","journal-title":"EMBO Rep."}],"container-title":["Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1074761324000384?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1074761324000384?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T02:50:26Z","timestamp":1739415026000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1074761324000384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":270,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S1074761324000384"],"URL":"https:\/\/doi.org\/10.1016\/j.immuni.2024.01.013","relation":{},"ISSN":["1074-7613"],"issn-type":[{"value":"1074-7613","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The B7:CD28 family and friends: Unraveling coinhibitory interactions","name":"articletitle","label":"Article Title"},{"value":"Immunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.immuni.2024.01.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}